The "Immunophenotyping by Flow Cytometry Leukemia Monitoring Panel-Hairy Cell Test" is a sophisticated diagnostic procedure used to identify and monitor hairy cell leukemia, a rare type of blood cancer. This test is conducted using flow cytometry, a technology that allows for the detailed analysis of the physical and chemical characteristics of cells in a fluid as they pass through a laser. Immunophenotyping specifically examines the types of proteins or markers found on the surface of cells, which can be crucial for diagnosing different forms of leukemia, including hairy cell leukemia.
This test is invaluable for healthcare professionals as it helps in confirming the diagnosis, determining the stage of the disease, and monitoring the patient's response to treatment. By identifying the unique immunophenotypic profile of the leukemia cells, doctors can tailor treatment plans to the specific needs of the patient, improving outcomes.
The test is available at DNA Labs UAE, a leading diagnostic center known for its state-of-the-art facilities and commitment to providing accurate and timely medical results. The cost of the test is 2180 AED, which reflects the intricate technology and expertise required to perform this advanced diagnostic procedure. Patients undergoing this test at DNA Labs UAE can expect a high standard of service and reliable results that are crucial for the effective management of hairy cell leukemia.
The HLA Cadaveric Crossmatch Test is a critical diagnostic procedure conducted to ensure compatibility between a donor's organ and a recipient's immune system before organ transplantation. This test focuses on the human leukocyte antigen (HLA) system, a group of genes that play a crucial role in the body's immune response. By evaluating the interaction between the recipient's serum and the donor's HLA, the test aims to predict the likelihood of the recipient's immune system rejecting the transplanted organ.
Performed at DNA Labs UAE, a facility known for its advanced diagnostic services and state-of-the-art technology, the HLA Cadaveric Crossmatch Test is a key step in the pre-transplantation process. Ensuring compatibility can significantly increase the success rate of organ transplants and improve the recipient's prognosis.
The cost of the HLA Cadaveric Crossmatch Test at DNA Labs UAE is 2,180 AED. This price reflects the complex nature of the test and the sophisticated equipment and expertise required to accurately analyze HLA compatibility. For patients and their families, investing in this test is a critical part of the journey towards a successful organ transplant, offering hope and a chance for a healthier future.
The "Achondroplasia Mutation Analysis FGFR3 Gene G1138A G1138C Test" is a specialized genetic test designed to detect specific mutations within the FGFR3 gene, known to be the primary cause of achondroplasia. Achondroplasia is the most common form of dwarfism, characterized by a particular type of short stature, disproportionately short limbs, and other skeletal abnormalities. The mutations of interest, G1138A and G1138C, occur in the FGFR3 gene and are pivotal in diagnosing this genetic condition accurately.
This test involves analyzing the patient's DNA to identify the presence of the G1138A or G1138C mutations in the FGFR3 gene. Early and precise detection of these mutations can aid in the diagnosis, management, and understanding of the condition, facilitating personalized care and interventions for individuals with achondroplasia.
Conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities, the test is priced at 550 AED. This cost includes the comprehensive analysis required to identify the specific mutations, providing invaluable information for affected individuals and their families. DNA Labs UAE employs state-of-the-art technology and adheres to stringent quality standards to ensure accurate and reliable test results.
The BCL2IGH t(14;18) test is a specialized diagnostic procedure designed to detect the presence of a specific chromosomal translocation between chromosomes 14 and 18, commonly referred to as t(14;18). This translocation results in the juxtaposition of the BCL2 gene on chromosome 18 next to the immunoglobulin heavy chain locus (IGH) on chromosome 14. The consequence of this genetic rearrangement is the overexpression of the BCL2 protein, which plays a crucial role in regulating cell death and is associated with the development of certain types of cancers, most notably follicular lymphoma.
The test employs sophisticated molecular biology techniques to identify the BCL2-IGH fusion gene, providing crucial information for the diagnosis, prognosis, and management of patients with suspected or confirmed lymphomas. It is particularly valuable in the clinical setting for its role in guiding treatment decisions and monitoring disease progression or response to therapy.
Conducted at DNA Labs UAE, a reputable facility known for its advanced diagnostic services, the BCL2IGH t(14;18) test is available for a cost of 1800 AED. The lab utilizes state-of-the-art technology and follows stringent quality control measures to ensure accurate and reliable results. Patients and healthcare providers considering this test can expect professionalism and confidentiality, along with comprehensive support throughout the testing process.
The BCL6 test is a diagnostic examination aimed at detecting the presence of the BCL6 gene rearrangement, which is often associated with certain types of lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. This test is crucial for the accurate diagnosis and management of these conditions, helping healthcare professionals to tailor treatment strategies according to the genetic makeup of the tumor.
Performed at DNA Labs UAE, a leading facility known for its comprehensive genetic testing services, the BCL6 test involves the analysis of a patient's DNA to identify mutations or alterations in the BCL6 gene. This gene plays a critical role in the development and function of B cells, which are a type of white blood cell. Abnormalities in the BCL6 gene can lead to uncontrolled cell growth, contributing to the development of lymphoma.
The cost of the BCL6 test at DNA Labs UAE is 1800 AED. This investment in health allows patients and their healthcare providers to access vital genetic information that can significantly influence treatment decisions and outcomes. By identifying the genetic alterations early, patients can receive more personalized and effective therapies, improving their chances of a better health outcome.
The BCR-ABL Variant Panel is a specialized genetic test aimed at detecting specific mutations within the BCR-ABL gene. This gene is most commonly associated with chronic myeloid leukemia (CML) and, to a lesser extent, acute lymphoblastic leukemia (ALL). The test specifically looks for the Mbcr-b2a2 (e13a2), b3a2 (e14a2), and b2a3 variants, which are indicative of the presence of the Philadelphia chromosome, a genetic abnormality found in the majority of CML cases and a portion of ALL cases.
The presence of these mutations is a critical factor in diagnosing these types of leukemia and plays a significant role in determining the most effective treatment plan. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have been developed to specifically target cells containing the BCR-ABL fusion protein, making the detection of these mutations particularly important for patient care.
The test cost is set at 1800 AED and is conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities. By offering this test, DNA Labs UAE provides essential diagnostic information that can significantly impact the treatment and management of patients with CML and ALL, potentially improving patient outcomes through personalized medicine.
BCR-ABL1 Quantification by DD PCR Test is a highly precise diagnostic procedure used to monitor the levels of the BCR-ABL1 fusion gene, a marker commonly associated with chronic myeloid leukemia (CML) and, in some cases, acute lymphoblastic leukemia (ALL). This test employs Droplet Digital PCR (ddPCR) technology, which allows for an extremely accurate quantification of the BCR-ABL1 gene transcripts, providing essential information for the diagnosis, prognosis, and monitoring of therapeutic response in patients with these hematologic malignancies.
Conducted at DNA Labs UAE, a facility renowned for its state-of-the-art diagnostic services, the BCR-ABL1 Quantification by DD PCR Test is pivotal for clinicians in tailoring the most effective treatment plans for their patients. By precisely measuring the amount of BCR-ABL1 gene expression, healthcare providers can assess the disease's progression, evaluate the effectiveness of specific therapies, and adjust treatment strategies accordingly.
The cost of the BCR-ABL1 Quantification by DD PCR Test at DNA Labs UAE is set at 1800 AED. This investment is crucial for those affected by conditions linked to the BCR-ABL1 gene, as it empowers patients and their healthcare teams with vital data to make informed decisions throughout the course of the disease and treatment.
The BCR-ABL1 Quantitative p210/p190/p230 Test is a highly specialized diagnostic examination offered by DNA Labs UAE, designed to detect the presence and measure the amount of the BCR-ABL1 fusion gene in a patient's blood or bone marrow. This fusion gene is a hallmark of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL), resulting from the translocation between chromosomes 9 and 22, known as the Philadelphia chromosome. The test specifically targets the three main types of BCR-ABL1 fusion proteins: p210, p190, and p230, each associated with different forms of leukemia.
The quantitative nature of this test allows for the precise monitoring of disease progression and response to therapy, making it an invaluable tool in the management of patients with CML and ALL. By measuring the levels of BCR-ABL1 over time, healthcare providers can adjust treatment strategies to achieve the best possible outcomes.
At DNA Labs UAE, the BCR-ABL1 Quantitative p210/p190/p230 Test is offered for 1800 AED. The test is conducted with state-of-the-art technology and under the guidance of experienced professionals, ensuring accurate and reliable results. Given its critical role in the diagnosis and management of leukemia, this test represents a significant investment in patient care, providing essential information for personalized treatment planning.
The "Beta Thalassemia - 12 Common Mutations Screening Single Test," available at DNA Labs UAE, is a specialized genetic test designed to detect the 12 most common mutations associated with Beta Thalassemia, a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body. Individuals with Beta Thalassemia may experience a range of symptoms from mild anemia to severe health complications, depending on the mutation and its impact on hemoglobin production.
This test is particularly important for individuals with a family history of thalassemia or those belonging to ethnic groups with a high prevalence of the disease. Early detection through this screening can provide crucial information for disease management, treatment planning, and informed family planning decisions. The test involves a simple blood draw, and the sample is analyzed to identify any of the 12 common mutations linked to Beta Thalassemia.
Offered at a cost of 1800 AED, the test is a valuable tool for at-risk individuals seeking to understand their genetic health and make proactive decisions regarding their well-being and that of their future offspring. DNA Labs UAE, known for its state-of-the-art genetic testing services, ensures confidentiality, accuracy, and timely results for all its clients.
The BKJC Qualitative PCR Test is a sophisticated diagnostic procedure designed to detect the presence of BK virus in patients, utilizing the highly accurate Polymerase Chain Reaction (PCR) methodology. This test is particularly vital for individuals who are at an increased risk of BK virus-related complications, such as transplant recipients and those with weakened immune systems. By targeting the genetic material of the virus, the PCR technique ensures a high level of sensitivity and specificity, making it a reliable tool for early detection and management of BK virus infections.
Conducted at DNA Labs UAE, a leading facility known for its advanced diagnostic technologies and expert staff, the test ensures that patients receive precise and timely results. The cost of the BKJC Qualitative PCR Test is set at 1800 AED, reflecting the intricate technology and professional expertise involved in the testing process. This investment is crucial for at-risk individuals, providing them with critical information that can guide treatment decisions and potentially prevent severe outcomes associated with BK virus infections.
